This bill amends Section 505(j) of the Federal Food, Drug, and Cosmetic Act to create a narrow route for a subsequent abbreviated new drug application (ANDA) to receive approval when a first applicant with potential 180‑day exclusivity fails to commence commercial marketing. It requires the later filer to certify readiness and intent to market and establishes a short marketing window tied to that certification; failing to meet the window causes reversion to tentative approval unless narrow cure conditions are met.
The change aims to prevent a single first‑filer from permanently blocking competition by sitting on an approval without launching the product, while preserving the basic 180‑day exclusivity framework. Companies, payers, and patients should expect faster market entry in some stalled cases; manufacturers and the FDA will face new compliance and monitoring tasks tied to the marketing certification and forfeiture mechanics.
At a Glance
What It Does
The bill adds a limited exception allowing FDA to make a subsequent ANDA effectively approvable when the original first applicant does not commercially market the drug, provided the later applicant certifies it can and will market within a defined short period and other timing conditions are met.
Who It Affects
Directly affects ANDA filers (first and subsequent applicants), branded companies that rely on 180‑day exclusivity, and FDA review staff; downstream impacts reach payers, state Medicaid programs, and purchasers who stand to gain earlier generic access in stalled cases.
Why It Matters
It recalibrates the Hatch‑Waxman incentive structure by removing some leverage from dormant first‑filers, potentially accelerating generic entry in specific stalled scenarios while introducing new verification and enforcement duties for FDA and compliance risks for applicants.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
Under current law, the first company to file a Paragraph IV ANDA challenging a brand patent can earn 180 days of market exclusivity once it obtains effective approval and begins commercial sales; that exclusivity can block other generics. This bill inserts an override: if the first filer sits on its approval and does not bring the drug to market, a later filer can ask FDA to make its approval effective instead.
To do so, the later filer must make a pointed certification to FDA that it can and will begin commercial marketing within a short, defined window after approval.
The statute sets out a sequence of gatekeeping conditions the later applicant must meet before FDA may approve it despite a pending first‑filer’s potential exclusivity. These conditions include how long the first filing process has been underway, that approval of the later ANDA would otherwise be ready to take effect, and that the later applicant explicitly pledges it will market quickly.
If FDA approves the later ANDA under the new pathway, that approval becomes effective only if the later applicant actually starts selling within the marketing window; failure to do so causes the effective approval to revert to tentative status.The bill also builds in a narrow cure mechanism: if the later applicant notifies FDA that an unforeseeable event prevented launching within the marketing window, it can regain effective approval only after certifying that the event was unforeseeable and that the obstacle has been fully resolved. Finally, the new rules apply only to ANDAs filed after enactment that concern drugs for which no Paragraph IV certification was already filed before the law took effect.
The net result is a conditional unlocking of the market when a first filer delays commercial entry, with statutory checks aimed at preventing opportunistic behavior.
The Five Things You Need to Know
The bill permits FDA to approve a subsequent ANDA over an eligible first applicant’s 180‑day exclusivity when the later applicant meets five statutory conditions, enabling the later approval to become effective despite the first filer’s prior status.
A later applicant must certify it can commence commercial marketing within 75 days after approval and that it intends to do so; the approval is contingent on actual marketing within that 75‑day window.
The statutory pathway is available only after at least 33 months have passed since at least one first applicant submitted its ANDA for the same drug.
If an approved subsequent applicant fails to start marketing within 75 days, its effective approval is automatically reverted to tentative status the day after the window closes; the applicant can only regain effective approval in limited circumstances after demonstrating an unforeseeable event prevented launch and the problem has been fully resolved.
The amendments apply solely to ANDAs filed after enactment that relate to listed drugs for which no Paragraph IV certification had been submitted prior to the law’s effective date.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Clarifies exclusivity linkage and preserves priority for a first filer who actually markets
This modification changes the cross‑references in the exclusivity provision so that the first‑filer’s entitlement to marketing exclusivity explicitly contemplates an alternate path created by a new subclause (III). It preserves the core rule that when a tentatively approved first applicant later meets all approval requirements and begins commercial marketing, other applicants may not receive effective approval until 180 days after that market start. Practically, this keeps the original incentive in place for any first filer that actually launches while allowing an alternate outcome if that launch does not occur.
Permits FDA to approve a subsequent applicant when tightly defined conditions are met
The new subclause lays out the exception: FDA may approve a later ANDA even though a first applicant remains eligible for 180‑day exclusivity, but only if all statutory conditions are satisfied. Those conditions require that the later approval could otherwise be made effective, the later applicant certifies readiness and intent to market quickly, a minimum elapsed time since the first filing has passed, approval of the first applicant is not barred for other legal reasons, and no first applicant’s approval is already effective on the day these conditions are met. This section is the operational core of the bill: it converts readiness‑to‑market commitments into a ticket for effective approval when the first filer stalls.
Creates an automatic forfeiture and narrow cure process for subsequent applicants who fail to market
This addition makes an approval granted under the new subclause (III) dependent on the later applicant actually commencing commercial sales within the declared short window; failure to do so causes the approval to revert to tentative status immediately after the window expires. The provision then gives the later applicant a limited opportunity to notify FDA that an unforeseeable event prevented launch; to regain effective approval the applicant must certify the event was unforeseeable and that it has fully resolved the issue. The clause also requires prompt notice to FDA once marketing does begin. These mechanics are designed to deter speculative approvals and ensure the pathway serves only firms ready to supply product quickly.
Limits the new pathway to post‑enactment ANDAs without prior Paragraph IV filings
The bill restricts its reach to ANDAs filed after enactment that concern drugs for which no Paragraph IV certification had been made before the law’s effective date. That temporal carve‑out prevents retroactive disturbance of existing Paragraph IV statuses and litigation positions, confining the rule change to future filings and preserving settled expectations for past challengers.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients and purchasers—When a first filer delays launch, insured patients, Medicare/Medicaid programs, and private payers may gain earlier access to lower‑priced generics because the pathway allows a ready later entrant to start sales sooner than under a strict exclusivity bar.
- Subsequent generic manufacturers—Companies that can manufacture and distribute quickly benefit from an explicit statutory route to convert tentative approvals into effective ones instead of being blocked indefinitely by an inactive first filer.
- State Medicaid programs and large payers—Earlier generic entry in stalled cases can reduce pharmacy spend and state rebate pressure, improving budget predictability for high‑cost drugs.
- Competition and market efficiency advocates—The rule narrows an avenue for strategic non‑launches that preserve high prices, increasing competitive pressure in specific stalled scenarios.
Who Bears the Cost
- First ANDA applicants and branded companies—Firms that intended to monetize exclusivity without immediate commercialization lose some leverage; the law reduces the protective value of an unlaunched approval.
- FDA—The agency will need to adjudicate readiness certifications, verify marketing starts, process cure notifications, and potentially defend new types of disputes or challenges, increasing administrative and litigation burdens for review divisions.
- Subsequent applicants—While they gain a pathway, they assume operational risk and compliance exposure: certifying ability to market within the short window creates risk of forfeiture and the need to document unforeseeable events to seek cure.
- Patent holders and parties to Hatch‑Waxman settlements—Earlier generic entry in some cases could undermine settlement strategies that relied on the blocking effect of an inactive first filer, producing legal and commercial uncertainty.
Key Issues
The Core Tension
The central dilemma is between preserving the original 180‑day incentive that motivates early patent challenges and preventing that incentive from becoming a tool to block competition indefinitely: strengthening one objective (rewarding first challengers) preserves a pathway to cheaper drugs, while prioritizing rapid access for patients risks weakening the financial incentive that produces patent‑challenging ANDAs in the first place.
The bill trades one form of market delay—an unlaunched first‑filer’s de facto block—for a new compliance regime built around self‑certifications and tight launch windows. That raises measurement and enforcement questions: FDA will need to define and verify what qualifies as ‘‘commercial marketing’’ (sales, distribution, or other activity), how to audit the 75‑day readiness claim, and what evidence satisfies the ‘‘unforeseeable event’’ cure standard.
Those operational definitions will determine whether the change meaningfully accelerates access or simply shifts litigation to new statutory terms.
The timing thresholds (notably the multi‑year waiting floor before a later applicant can use the pathway) create incentives for strategic behavior on both sides. First filers may accelerate launches that are logistically fragile to lock out others, or conversely seek to trigger exceptions that keep their tentative status.
Later filers face a race to be production‑ready and to document supply chains, quality, and distribution in advance; rushing to meet a 75‑day window could increase product‑quality risk or lead to short supplies. Finally, courts may be asked to resolve borderline questions left vague in the text—how to treat partial launches, bundled commercial activities, or staggered introductions—so litigation risk shifts rather than disappears.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.